Meta-analysis of revascularization versus medical therapy for atherosclerotic renal artery stenosis

Irbaz B. Riaz, Muhammad Husnain, Haris Riaz, Majid Asawaeer, Jawad Bilal, Anil Pandit, Ranjith Shetty, Kwan S Lee

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The aim of the study was to compare the efficacy of revascularization versus medical therapy in patients with atherosclerotic renal artery stenosis (ARAS). ARAS is the most common cause of secondary hypertension and is associated with several complications, such as renal failure, coronary artery disease, cardiac destabilization, and stroke. Medical therapy is the cornerstone for management of ARAS; however, numerous trials have compared medical therapy with revascularization in the form of percutaneous renal artery angioplasty (PTRA) or percutaneous renal artery angioplasty with stent placement (PTRAS). Medline (PubMed and Ovid SP), Embase, Cochrane Central Register of Controlled Clinical Trials (CENTRAL), and Cochrane Database of Systematic Review (CDSR) were searched till present (November 2013) to identify clinical trials where medical therapy was compared with revascularization (PTRA or PTRAS). We performed a meta-analysis using a random effects model. The heterogeneity was assessed using I<sup>2</sup> values. The initial database search identified 540 studies and 7 randomized controlled trials, and 2,139 patients were included in the final analysis. Angioplasty with or without stenting was not superior to medical therapy with respect to any outcome. The incidence of nonfatal myocardial infarction was 6.74% in both the stenting and medical therapy group (odds ratio = 0.998, 95% confidence interval 0.698 to 1.427, p = 0.992), and incidence of renal events in stenting population was found to be 19.58% versus 20.53% in medical therapy (odds ratio = 0.945, 95% confidence interval 0.755 to 1.182, p = 0.620). In conclusion, PTRA or PTRAS does not improve outcomes compared with medical therapy in patients with ARAS. Future studies should investigate to identify patient subgroups that may benefit from such an intervention.

Original languageEnglish (US)
Pages (from-to)1116-1123
Number of pages8
JournalThe American journal of cardiology
Volume114
Issue number7
DOIs
StatePublished - Oct 1 2014

Fingerprint

Renal Artery Obstruction
Meta-Analysis
Angioplasty
Renal Artery
Therapeutics
Odds Ratio
Databases
Confidence Intervals
Incidence
Controlled Clinical Trials
Group Psychotherapy
PubMed
Stents
Renal Insufficiency
Coronary Artery Disease
Randomized Controlled Trials
Stroke
Myocardial Infarction
Clinical Trials
Hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Meta-analysis of revascularization versus medical therapy for atherosclerotic renal artery stenosis. / Riaz, Irbaz B.; Husnain, Muhammad; Riaz, Haris; Asawaeer, Majid; Bilal, Jawad; Pandit, Anil; Shetty, Ranjith; Lee, Kwan S.

In: The American journal of cardiology, Vol. 114, No. 7, 01.10.2014, p. 1116-1123.

Research output: Contribution to journalArticle

Riaz, Irbaz B. ; Husnain, Muhammad ; Riaz, Haris ; Asawaeer, Majid ; Bilal, Jawad ; Pandit, Anil ; Shetty, Ranjith ; Lee, Kwan S. / Meta-analysis of revascularization versus medical therapy for atherosclerotic renal artery stenosis. In: The American journal of cardiology. 2014 ; Vol. 114, No. 7. pp. 1116-1123.
@article{fb85dfc5a64b46a38b21d2224c95a20d,
title = "Meta-analysis of revascularization versus medical therapy for atherosclerotic renal artery stenosis",
abstract = "The aim of the study was to compare the efficacy of revascularization versus medical therapy in patients with atherosclerotic renal artery stenosis (ARAS). ARAS is the most common cause of secondary hypertension and is associated with several complications, such as renal failure, coronary artery disease, cardiac destabilization, and stroke. Medical therapy is the cornerstone for management of ARAS; however, numerous trials have compared medical therapy with revascularization in the form of percutaneous renal artery angioplasty (PTRA) or percutaneous renal artery angioplasty with stent placement (PTRAS). Medline (PubMed and Ovid SP), Embase, Cochrane Central Register of Controlled Clinical Trials (CENTRAL), and Cochrane Database of Systematic Review (CDSR) were searched till present (November 2013) to identify clinical trials where medical therapy was compared with revascularization (PTRA or PTRAS). We performed a meta-analysis using a random effects model. The heterogeneity was assessed using I2 values. The initial database search identified 540 studies and 7 randomized controlled trials, and 2,139 patients were included in the final analysis. Angioplasty with or without stenting was not superior to medical therapy with respect to any outcome. The incidence of nonfatal myocardial infarction was 6.74{\%} in both the stenting and medical therapy group (odds ratio = 0.998, 95{\%} confidence interval 0.698 to 1.427, p = 0.992), and incidence of renal events in stenting population was found to be 19.58{\%} versus 20.53{\%} in medical therapy (odds ratio = 0.945, 95{\%} confidence interval 0.755 to 1.182, p = 0.620). In conclusion, PTRA or PTRAS does not improve outcomes compared with medical therapy in patients with ARAS. Future studies should investigate to identify patient subgroups that may benefit from such an intervention.",
author = "Riaz, {Irbaz B.} and Muhammad Husnain and Haris Riaz and Majid Asawaeer and Jawad Bilal and Anil Pandit and Ranjith Shetty and Lee, {Kwan S}",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.amjcard.2014.06.033",
language = "English (US)",
volume = "114",
pages = "1116--1123",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Meta-analysis of revascularization versus medical therapy for atherosclerotic renal artery stenosis

AU - Riaz, Irbaz B.

AU - Husnain, Muhammad

AU - Riaz, Haris

AU - Asawaeer, Majid

AU - Bilal, Jawad

AU - Pandit, Anil

AU - Shetty, Ranjith

AU - Lee, Kwan S

PY - 2014/10/1

Y1 - 2014/10/1

N2 - The aim of the study was to compare the efficacy of revascularization versus medical therapy in patients with atherosclerotic renal artery stenosis (ARAS). ARAS is the most common cause of secondary hypertension and is associated with several complications, such as renal failure, coronary artery disease, cardiac destabilization, and stroke. Medical therapy is the cornerstone for management of ARAS; however, numerous trials have compared medical therapy with revascularization in the form of percutaneous renal artery angioplasty (PTRA) or percutaneous renal artery angioplasty with stent placement (PTRAS). Medline (PubMed and Ovid SP), Embase, Cochrane Central Register of Controlled Clinical Trials (CENTRAL), and Cochrane Database of Systematic Review (CDSR) were searched till present (November 2013) to identify clinical trials where medical therapy was compared with revascularization (PTRA or PTRAS). We performed a meta-analysis using a random effects model. The heterogeneity was assessed using I2 values. The initial database search identified 540 studies and 7 randomized controlled trials, and 2,139 patients were included in the final analysis. Angioplasty with or without stenting was not superior to medical therapy with respect to any outcome. The incidence of nonfatal myocardial infarction was 6.74% in both the stenting and medical therapy group (odds ratio = 0.998, 95% confidence interval 0.698 to 1.427, p = 0.992), and incidence of renal events in stenting population was found to be 19.58% versus 20.53% in medical therapy (odds ratio = 0.945, 95% confidence interval 0.755 to 1.182, p = 0.620). In conclusion, PTRA or PTRAS does not improve outcomes compared with medical therapy in patients with ARAS. Future studies should investigate to identify patient subgroups that may benefit from such an intervention.

AB - The aim of the study was to compare the efficacy of revascularization versus medical therapy in patients with atherosclerotic renal artery stenosis (ARAS). ARAS is the most common cause of secondary hypertension and is associated with several complications, such as renal failure, coronary artery disease, cardiac destabilization, and stroke. Medical therapy is the cornerstone for management of ARAS; however, numerous trials have compared medical therapy with revascularization in the form of percutaneous renal artery angioplasty (PTRA) or percutaneous renal artery angioplasty with stent placement (PTRAS). Medline (PubMed and Ovid SP), Embase, Cochrane Central Register of Controlled Clinical Trials (CENTRAL), and Cochrane Database of Systematic Review (CDSR) were searched till present (November 2013) to identify clinical trials where medical therapy was compared with revascularization (PTRA or PTRAS). We performed a meta-analysis using a random effects model. The heterogeneity was assessed using I2 values. The initial database search identified 540 studies and 7 randomized controlled trials, and 2,139 patients were included in the final analysis. Angioplasty with or without stenting was not superior to medical therapy with respect to any outcome. The incidence of nonfatal myocardial infarction was 6.74% in both the stenting and medical therapy group (odds ratio = 0.998, 95% confidence interval 0.698 to 1.427, p = 0.992), and incidence of renal events in stenting population was found to be 19.58% versus 20.53% in medical therapy (odds ratio = 0.945, 95% confidence interval 0.755 to 1.182, p = 0.620). In conclusion, PTRA or PTRAS does not improve outcomes compared with medical therapy in patients with ARAS. Future studies should investigate to identify patient subgroups that may benefit from such an intervention.

UR - http://www.scopus.com/inward/record.url?scp=84909631461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909631461&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2014.06.033

DO - 10.1016/j.amjcard.2014.06.033

M3 - Article

C2 - 25145333

AN - SCOPUS:84909631461

VL - 114

SP - 1116

EP - 1123

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 7

ER -